News and Press Releases
Medigene AG Announces Lead Selection for MDG2021,Expanding TCR-T KRAS Library Targeting Solid Tumours
20 June 2024, Planegg/Martinsried, Germany- Medigene AG (Medigene, the “company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Category: Drug Delivery
Posted: June 20, 2024
Bio-Rad Launches ddSEQ Single-Cell 3′ RNA-Seq Kit for Single-Cell Gene Expression
ddSEQ single-cell 3' RNA-Seq kit and Omnition v1.1 analysis software enable high-quality and affordable single-cell transcription and gene expression to support molecular biology, oncology and drug discovery research 19 June...
Category: Drug Discovery, Other, Pharmaceutical
Posted: June 19, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK - STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 17, 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData
14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...
Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange
11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024
Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid...
Category: Biotechnology, Manufacturing and Packing, Pharmaceutical
Posted: June 6, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities
16 May 2024 -- Laval, Québec, Canada -- Altasciences announced today that it has been recognised for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This...
Category: BioManufacturing, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting
2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 2, 2024
